Chambers Review
Provided by Chambers
Contact number
+852 3740 6888Share profile
Band 3
Provided by Paloma Wang
Corporate
Ms. Wang joined Skadden in 2018 from another leading law firm, where she was a partner.
Admitted in Hong Kong and England & Wales. Currently practising in Hong Kong.
Recent publications include:
2020 Corporate Governance Survey of Hong Kong-listed Biotech Companies, March 2021;
Are You Ready for a Hong Kong IPO?, September 2021; and
Hong Kong Encourages Listings by Foreign Companies, SPACs, Skadden Insights, January 2022.
Paloma Wang’s practice focuses on public listings and other corporate matters. She represents both issuers and underwriters in initial public offerings on the Hong Kong Stock Exchange, advising investors and corporates on private equity investments and counseling listed issuers on compliance, general corporate and regulatory matters.
Ms. Wang advised on the three largest Hong Kong listings in 2020 (for JD.com, Inc.; JD Health International Inc.; and NetEase, Inc.), the second largest Hong Kong IPO in 2021 (for JD Logistics, Inc.), four of the five largest Hong Kong secondary listings in 2020 (for JD.com, Inc.; NetEase, Inc.; New Oriental Education & Technology Group Inc.; and ZTO Express (Cayman) Inc.), and all of the Hong Kong secondary listings in 2021 (Autohome Inc.; Baidu, Inc.; Bilibili Inc.; Trip.com Group Limited; and Weibo Corporation).
Ms. Wang is a market leader in advising in the biotech and life sciences sector, TMT/new economy companies with WVR structures and "Homecoming" companies with secondary listings in Hong Kong.
Hong Kong
Cantonese, English and Mandarin
City University of Hong Kong
PCLL
2003
University of Oxford
B.A. Law
2002
China University of Politics and Law
B.A.
1999
IPO Lawyer of the Year
ALM Asia Legal Awards
2021
Rising Star Partner for Equity Capital Markets
IFLR1000
2022
Provided by Chambers